Organon & Co. (NYSE:OGN) Stock Rating Lowered by Wall Street Zen

Organon & Co. (NYSE:OGN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other research analysts also recently issued reports on the stock. Morgan Stanley reduced their price target on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 11th. Barclays initiated coverage on shares of Organon & Co. in a research note on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 target price for the company. JPMorgan Chase & Co. reduced their target price on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 11th. Piper Sandler cut shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target on the stock. in a research note on Monday, October 27th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Organon & Co. presently has an average rating of “Reduce” and an average price target of $8.38.

Organon & Co. Stock Down 1.0%

NYSE OGN opened at $8.51 on Friday. The stock’s 50 day simple moving average is $7.80 and its 200 day simple moving average is $8.73. Organon & Co. has a one year low of $6.18 and a one year high of $17.23. The firm has a market cap of $2.21 billion, a PE ratio of 4.43, a price-to-earnings-growth ratio of 1.84 and a beta of 0.58. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Monday, November 10th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.08. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.During the same quarter in the previous year, the firm earned $1.38 earnings per share. As a group, sell-side analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Organon & Co.

A number of institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada lifted its stake in Organon & Co. by 53.4% in the first quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock valued at $5,374,000 after buying an additional 125,648 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after buying an additional 801,307 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Organon & Co. by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock valued at $15,530,000 after acquiring an additional 26,640 shares during the last quarter. Focus Partners Wealth increased its stake in shares of Organon & Co. by 33.2% in the 1st quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock valued at $832,000 after acquiring an additional 13,925 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Organon & Co. by 57.6% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 56,112 shares of the company’s stock valued at $559,000 after acquiring an additional 20,507 shares during the period. 77.43% of the stock is owned by institutional investors and hedge funds.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.